Paper of the Month - November, 2012

0 rating

Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Shulman LN, Cirrincione CT, Berry DA et al.
In this study, the authors compared the impact of four versus six cycles of adjuvant anthracycline and taxane-based chemotherapy regimens in lower-risk breast cancer patients.


READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE